
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is considered a positive investment opportunity based on their continued growth in revenue, especially in their NGS segment which is expected to drive double-digit growth over the next three years. Furthermore, the company's optimization efforts and increasing ASP are expected to improve margins and cash flow. The company also has a wide range of oncology diagnostic tests and a strong position in the community channel for cancer care, making it an attractive investment opportunity.
Bears say
NeoGenomics is a clinical laboratory company with a negative outlook due to potential risks such as weaker than expected EBITDA margins, negative reimbursement changes, and potential market share loss to competitors. Additionally, the company's launch of a genomic-based malignancy profiling test is not expected for the next two years and they have not disclosed overall exposure to this market, suggesting potential challenges in this segment. This, combined with a current EV/sales multiple of ~3.0x, may result in a lower valuation and weaker financial performance for NeoGenomics in the future.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares